Keiko Minashi

Chiba, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: June 18, 2026

Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A.

Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A.

Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Published: March 29, 2026

Nationwide quality indicator survey on the current practice of esophageal cancer management in Japan: report from the guideline committee for the 6th edition of the Japanese Esophageal Cancer Practice Guidelines.

Nationwide quality indicator survey on the current practice of esophageal cancer management in Japan: report from the guideline committee for the 6th edition of the Japanese Esophageal Cancer Practice Guidelines.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: February 13, 2026

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma.

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.

Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: December 18, 2025

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Journal: Targeted oncology

Published: November 17, 2025

Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.

Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.

Journal: Annals of surgical oncology

Published: October 14, 2025

Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.

Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.

Journal: Japanese journal of clinical oncology

Published: September 03, 2025

Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial.

Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial.

Journal: EClinicalMedicine

Published: August 27, 2025

Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.

Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: June 30, 2025

A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G.

A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G.

Journal: Future oncology (London, England)

Published: June 06, 2025

Showing 1-12 of 71

Last Updated: 09/26/2026